Who Paid My Doc
Jennifer Leinicke
Colon & Rectal Surgery Omaha, NE Medical Doctor
NPI 1093905572 CMS profile 650819
4014 Leavenworth St, Omaha, NE 68105
General payments
$563
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jennifer Leinicke of Omaha, NE is reported in the CMS Open Payments database as having received $563 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 23rd percentile of Colon & Rectal Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $168 | 1 | |
| 2023 | General | $395 | 1 |
Beside peers
- Jennifer Leinicke
- Colon & Rectal Surgery median
- Middle half of Colon & Rectal Surgery
- National median
In program year 2025, general payments to Jennifer Leinicke were reported at $168. Among 1,481 Colon & Rectal Surgery profiles paid that year, the median was $317 and the middle half received between $109 and $1,248.
Show as a table
| Year | Jennifer Leinicke | Colon & Rectal Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $443 | $125–$2,179 | $163 |
| 2020 | $0 | $167 | $53–$931 | $114 |
| 2021 | $0 | $207 | $72–$1,272 | $132 |
| 2022 | $0 | $341 | $111–$1,587 | $149 |
| 2023 | $395 | $322 | $115–$1,420 | $160 |
| 2024 | $0 | $328 | $112–$1,354 | $164 |
| 2025 | $168 | $317 | $109–$1,248 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 49 billing codesPaid by Medicare
$38,723
Medicare patients
122
Services billed
287
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 60% | |
| Cancer | 39% | |
| Depression | 29% | |
| Chronic kidney disease | 27% | |
| Diabetes | 24% | |
| Ischemic heart disease | 23% | |
| Atrial fibrillation | 20% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Colon & Rectal Surgery in Nebraska
Michael Jobst
Colon & Rectal Surgery · Lincoln, NE
Alan Thorson
Colon & Rectal Surgery · Omaha, NE
Hernan Hernandez
Colon & Rectal Surgery · Omaha, NE
Charles Ternent
Colon & Rectal Surgery · Omaha, NE
Austin Person
Colon & Rectal Surgery · Omaha, NE
Zachary Torgersen
Colon & Rectal Surgery · Omaha, NE
Related records
Colon & Rectal Surgery in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Colon & Rectal Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.